Germany’s cannabis reform faces fresh legal and political pressure as KCanG disputes mount

A club lawsuit pushes Bavaria’s planning rules into focus

The latest legal challenge comes from the German Hemp Association and CSC Inntal, which have filed suit after a municipal building-law approval was refused. According to the association’s own reporting, the case is meant to force a basic clarification of how cannabis cultivation associations are classified under building law in Bavaria, not just to resolve a single permit dispute in the DHV’s account of the case.

That matters because club licensing under the KCanG has already been slow and uneven across Germany. The Bavarian dispute is now one more example of how the reform’s administrative layer can become a bottleneck even where the federal law itself is in force. The DHV has said it is financing the litigation to obtain a principled answer on the planning-law status of cultivation associations in the state in its news update.

Streeck signals openness to model projects, but only narrowly

On the federal policy side, the current Bundesdrogenbeauftragter, Hendrik Streeck, has taken a more open line toward limited model experiments. In remarks reported by RND, he said he would be open to model projects for legal cannabis sales, but only under very strict conditions in the first RND report.

That position is not the same as a broad endorsement of retail liberalisation. Other reporting cited in the research pool shows Streeck stressing tighter rules, clearer legal pathways for consumers and a tougher line on misuse. He has also been reported as wanting stricter, more coherent cannabis rules and warning about easy access and rising potency in illicit drugs as Tagesspiegel and n-tv noted, and as WELT reported.

That tension — between cautious openness to testing and a broader instinct for restriction — is important because Germany’s second pillar remains unresolved. The government has already delayed more ambitious retail plans, leaving scientific pilot regions and tightly supervised trials as the main bridge between the current partial legalization and any broader market model as described in the discussion of Pillar 2 delays.

Two years in, the reform is still producing mixed verdicts

The broader assessment of Germany’s KCanG is still unsettled. On the law’s second anniversary, DW reported that conservatives were calling the cannabis law a nonstarter, while other observers treated the interim review as evidence of a reform that has changed the market without yet settling the legal and enforcement debate in DW’s April report.

That critique is reinforced by regional reporting from the states. NDR reported that six cannabis clubs had been established in Mecklenburg-Vorpommern, yet the black market was still flourishing there, a reminder that legalization has not automatically displaced illicit supply in NDR’s report from May. At the same time, police enforcement remained active elsewhere, including a February seizure of 700 cannabis plants in Lamspringe as NDR reported.

Other reporting in the research pool points in the same direction: the first year after legalization was widely described as mixed, permit approvals were slow, and officials continued to debate how to manage the law’s enforcement burden as DW reported in 2025, while ZEIT reported criticism from the BKA chief that the black market remained a problem despite the new framework in its March 2026 coverage.

Medical cannabis is scaling fast even as access rules tighten

The medical side of the market is moving in a very different direction from the club debate. Several reports in the research set say Germany’s medical-cannabis market has expanded sharply since the 2024 reform, with prescription volumes surging and imports rising before a recent slowdown as summarized in High Times and related market coverage.

One of the clearest figures in that coverage is the reported rise in medical-cannabis prescriptions by more than 3,300% by December 2025 compared with March 2024. That figure sits alongside a report that Germany imported 50.5 tonnes in Q1 2026, the first quarterly decline since early 2024 as reported by Hanf Magazin.

But the market is also running into access and compliance constraints. MDR reported that the government was planning to require in-person doctor visits for prescriptions and to restrict mail-order sales, while a separate piece in the research pool said only about one in ten general practitioners would prescribe medical cannabis as health-policy reporting noted, and as Health Policy Online reported.

What the evaluation cycle could mean for the next phase

Germany’s reform is now moving through the evaluation phase that was always built into the KCanG debate. The research pool references key review dates of 1 October 2025 and 1 April 2026, showing that lawmakers, regulators and commentators are already reading the law through the lens of staged assessment rather than a fixed endpoint as Cannastreet outlined.

That staged approach helps explain why the political debate keeps returning to model projects. Researchers and policy observers are still pushing for the second pillar, while the government has been cautious about retail pilots and the broader commercial framework remains unresolved as the research summaries on Pillar 2 note.

For now, the debate has three live fronts: the legality and classification of clubs, the future shape of medical access, and whether Germany will eventually allow tightly supervised retail experiments. The latest lawsuit in Bavaria, Streeck’s guarded openness to model projects, and the mixed post-reform evaluations all point to the same conclusion: the KCanG is not settling down, but being renegotiated in real time.